ArticleJournal of managed care & specialty pharmacy2020

A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER".

Sarika Ogale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.